Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 85
Filtrar
1.
Proc Natl Acad Sci U S A ; 119(14): e2123268119, 2022 04 05.
Artigo em Inglês | MEDLINE | ID: mdl-35349335

RESUMO

SignificanceMany gram-positive organisms have evolved an elegant solution to sense and resist antimicrobial peptides that inhibit cell-wall synthesis. These organisms express an unusual "Bce-type" adenosine triphosphate-binding cassette (ABC) transporter that recognizes complexes formed between antimicrobial peptides and lipids involved in cell-wall biosynthesis. In this work, we provide the first structural snapshots of a Bce-type ABC transporter trapped in different conformational states. Our structures and associated biochemical data provide key insights into the novel target protection mechanism that these unusual ABC transporters use to sense and resist antimicrobial peptides. The studies described herein set the stage to begin developing a comprehensive molecular understanding of the diverse interactions between antimicrobial peptides and conserved resistance machinery found across most gram-positive organisms.


Assuntos
Bacitracina , Farmacorresistência Bacteriana , Transportadores de Cassetes de Ligação de ATP/metabolismo , Antibacterianos/farmacologia , Bacillus subtilis/metabolismo , Bacitracina/metabolismo , Bacitracina/farmacologia , Proteínas de Bactérias/metabolismo , Regulação Bacteriana da Expressão Gênica , Proteínas de Membrana Transportadoras/metabolismo
2.
J Bacteriol ; 206(3): e0001524, 2024 Mar 21.
Artigo em Inglês | MEDLINE | ID: mdl-38323910

RESUMO

Antibiotics that inhibit peptidoglycan synthesis trigger the activation of both specific and general protective responses. σM responds to diverse antibiotics that inhibit cell wall synthesis. Here, we demonstrate that cell wall-inhibiting drugs, such as bacitracin and cefuroxime, induce the σM-dependent ytpAB operon. YtpA is a predicted hydrolase previously proposed to generate the putative lysophospholipid antibiotic bacilysocin (lysophosphatidylglycerol), and YtpB is the branchpoint enzyme for the synthesis of membrane-localized C35 terpenoids. Using targeted lipidomics, we reveal that YtpA is not required for the production of lysophosphatidylglycerol. Nevertheless, ytpA was critical for growth in a mutant strain defective for homeoviscous adaptation due to a lack of genes for the synthesis of branched chain fatty acids and the Des phospholipid desaturase. Consistently, overexpression of ytpA increased membrane fluidity as monitored by fluorescence anisotropy. The ytpA gene contributes to bacitracin resistance in mutants additionally lacking the bceAB or bcrC genes, which directly mediate bacitracin resistance. These epistatic interactions support a model in which σM-dependent induction of the ytpAB operon helps cells tolerate bacitracin stress, either by facilitating the flipping of the undecaprenyl phosphate carrier lipid or by impacting the assembly or function of membrane-associated complexes involved in cell wall homeostasis.IMPORTANCEPeptidoglycan synthesis inhibitors include some of our most important antibiotics. In Bacillus subtilis, peptidoglycan synthesis inhibitors induce the σM regulon, which is critical for intrinsic antibiotic resistance. The σM-dependent ytpAB operon encodes a predicted hydrolase (YtpA) and the enzyme that initiates the synthesis of C35 terpenoids (YtpB). Our results suggest that YtpA is critical in cells defective in homeoviscous adaptation. Furthermore, we find that YtpA functions cooperatively with the BceAB and BcrC proteins in conferring intrinsic resistance to bacitracin, a peptide antibiotic that binds tightly to the undecaprenyl-pyrophosphate lipid carrier that sustains peptidoglycan synthesis.


Assuntos
Bacillus subtilis , Bacitracina , Bacitracina/farmacologia , Bacitracina/metabolismo , Bacillus subtilis/genética , Peptidoglicano/metabolismo , Antibacterianos/farmacologia , Antibacterianos/metabolismo , Parede Celular/metabolismo , Membrana Celular/metabolismo , Óperon , Hidrolases/metabolismo , Lipídeos , Proteínas de Bactérias/genética , Proteínas de Bactérias/metabolismo
3.
Curr Microbiol ; 80(5): 135, 2023 Mar 13.
Artigo em Inglês | MEDLINE | ID: mdl-36913050

RESUMO

Staphylococcus aureus is one of the important pathogens causing human diseases, especially its treatment has great challenges due to its resistance to methicillin and vancomycin. The Bacillus strains are known to be major sources of second metabolites that can function as drugs. Therefore, it is of great value to excavate metabolites with good inhibitory activity against S. aureus from Bacillus strains. In this study, a strain Bacillus paralicheniformis CPL618 with good antagonistic activity against S. aureus was isolated and genome analysis showed that the size was 4,447,938 bp and contained four gene clusters fen, bac, dhb, and lch which are potentially responsible for four cyclic peptides fengycin, bacitracin, bacillibactin, and lichenysin biosynthesis, respectively. These gene clusters were knockout by homologous recombination. The bacteriostatic experiment results showed that the antibacterial activity of ∆bac decreased 72.3% while Δfen, Δdhb, and ΔlchA did not significantly changed as that of wild type. Interestingly, the maximum bacitracin yield was up to 92 U/mL in the LB medium, which was extremely unusual in wild type strains. To further improve the production of bacitracin, transcription regulators abrB and lrp were knocked out, the bacitracin produced by ΔabrB, Δlrp, and ΔabrB + lrp was 124 U/mL, 112 U/mL, and 160 U/ml, respectively. Although no new anti-S. aureus compounds was found by using genome mining in this study, the molecular mechanisms of high yield of bacitracin and anti-S. aureus in B. paralicheniformis CPL618 were clarified. Moreover, B. paralicheniformis CPL618 was further genetically engineered for industrial production of bacitracin.


Assuntos
Bacillus , Bacitracina , Humanos , Bacitracina/farmacologia , Bacitracina/metabolismo , Bacillus/genética , Bacillus/metabolismo , Antibacterianos/farmacologia , Antibacterianos/metabolismo , Engenharia Genética
4.
Mol Microbiol ; 115(1): 157-174, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-32955745

RESUMO

Bacteria closely control gene expression to ensure optimal physiological responses to their environment. Such careful gene expression can minimize the fitness cost associated with antibiotic resistance. We previously described a novel regulatory logic in Bacillus subtilis enabling the cell to directly monitor its need for detoxification. This cost-effective strategy is achieved via a two-component regulatory system (BceRS) working in a sensory complex with an ABC-transporter (BceAB), together acting as a flux-sensor where signaling is proportional to transport activity. How this is realized at the molecular level has remained unknown. Using experimentation and computation we here show that the histidine kinase is activated by piston-like displacements in the membrane, which are converted to helical rotations in the catalytic core via an intervening HAMP-like domain. Intriguingly, the transporter was not only required for kinase activation, but also to actively maintain the kinase in its inactive state in the absence of antibiotics. Such coupling of kinase activity to that of the transporter ensures the complete control required for transport flux-dependent signaling. Moreover, we show that the transporter likely conserves energy by signaling with sub-maximal sensitivity. These results provide the first mechanistic insights into transport flux-dependent signaling, a unique strategy for energy-efficient decision making.


Assuntos
Transportadores de Cassetes de Ligação de ATP/metabolismo , Bacillus subtilis/metabolismo , Histidina Quinase/metabolismo , Transportadores de Cassetes de Ligação de ATP/fisiologia , Antibacterianos/farmacologia , Bacillus subtilis/genética , Bacitracina/metabolismo , Bacitracina/farmacologia , Proteínas de Bactérias/metabolismo , Farmacorresistência Bacteriana/genética , Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos , Regulação Bacteriana da Expressão Gênica/genética , Histidina Quinase/fisiologia , Proteínas de Membrana Transportadoras/metabolismo , Transdução de Sinais/efeitos dos fármacos
5.
Bioconjug Chem ; 33(4): 555-559, 2022 04 20.
Artigo em Inglês | MEDLINE | ID: mdl-35319881

RESUMO

Endogenous Staphylococcus aureus sortase A (SrtA) covalently incorporates cell wall anchored proteins equipped with a SrtA recognition motif (LPXTG) via a lipid II-dependent pathway into the staphylococcal peptidoglycan layer. Previously, we found that the endogenous S. aureus SrtA is able to recognize and process a variety of exogenously added synthetic SrtA substrates, including K(FITC)LPMTG-amide and K(FITC)-K-vancomycin-LPMTG-amide. These synthetic substrates are covalently incorporated into the bacterial peptidoglycan (PG) of S. aureus with varying efficiencies. In this study, we examined if native and synthetic substrates are processed by SrtA via the same pathway. Therefore, the effect of the lipid II inhibiting antibiotic bacitracin on the incorporation of native and synthetic SrtA substrates was assessed. Treatment of S. aureus with bacitracin resulted in a decreased incorporation of protein A in the bacterial cell wall, whereas incorporation of exogenous synthetic substrates was increased. These results suggest that natural and exogenous synthetic substrates are processed by S. aureus via different pathways.


Assuntos
Peptidoglicano , Staphylococcus aureus , Amidas , Aminoaciltransferases , Bacitracina/metabolismo , Bacitracina/farmacologia , Proteínas de Bactérias/metabolismo , Cisteína Endopeptidases , Fluoresceína-5-Isotiocianato , Peptidoglicano/metabolismo
6.
Microbiology (Reading) ; 165(4): 475-487, 2019 04.
Artigo em Inglês | MEDLINE | ID: mdl-30777814

RESUMO

Bacitracin is a cell wall targeting antimicrobial with clinical and agricultural applications. With the growing mismatch between antimicrobial resistance and development, it is essential we understand the molecular mechanisms of resistance in order to prioritize and generate new effective antimicrobials. BcrR is a unique membrane-bound one-component system that regulates high-level bacitracin resistance in Enterococcus faecalis. In the presence of bacitracin, BcrR activates transcription of the bcrABD operon conferring resistance through a putative ATP-binding cassette (ABC) transporter (BcrAB). BcrR has three putative functional domains, an N-terminal helix-turn-helix DNA-binding domain, an intermediate oligomerization domain and a C-terminal transmembrane domain. However, the molecular mechanisms of signal transduction remain unknown. Random mutagenesis of bcrR was performed to generate loss- and gain-of-function mutants using transcriptional reporters fused to the target promoter PbcrA. Fifteen unique mutants were isolated across all three proposed functional domains, comprising 14 loss-of-function and one gain-of-function mutant. The gain-of-function variant (G64D) mapped to the putative dimerization domain of BcrR, and functional analyses indicated that the G64D mutant constitutively expresses the PbcrA-luxABCDE reporter. DNA-binding and membrane insertion were not affected in the five mutants chosen for further characterization. Homology modelling revealed putative roles for two key residues (R11 and S33) in BcrR activation. Here we present a new model of BcrR activation and signal transduction, providing valuable insight into the functional characterization of membrane-bound one-component systems and how they can coordinate critical bacterial responses, such as antimicrobial resistance.


Assuntos
Transportadores de Cassetes de Ligação de ATP/metabolismo , Bacitracina/metabolismo , Membrana Celular/metabolismo , Farmacorresistência Bacteriana , Transdução de Sinais/fisiologia , Transportadores de Cassetes de Ligação de ATP/química , Transportadores de Cassetes de Ligação de ATP/genética , Antibacterianos/farmacologia , Bacillus subtilis/efeitos dos fármacos , Bacillus subtilis/genética , Bacitracina/farmacologia , Farmacorresistência Bacteriana/genética , Enterococcus faecalis/efeitos dos fármacos , Enterococcus faecalis/genética , Regulação Bacteriana da Expressão Gênica , Genes Bacterianos/genética , Mutação , Óperon , Regiões Promotoras Genéticas , Ligação Proteica , Domínios Proteicos
7.
Appl Microbiol Biotechnol ; 103(20): 8383-8392, 2019 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-31494703

RESUMO

Bacitracin is a cyclic dodecyl peptide antibiotic that is an effective bacteriocide against Gram-positive and some Gram-negative bacteria. Bacitracin has been widely used as an antibacterial feed additive for livestock since it is not absorbed easily by the intestine and is easily excreted. Precursor availability has been proven to be one of the core factors for bacitracin production by many previous studies. In this study, we focused on enhancing the supply of the precursor amino acid L-ornithine to enhance bacitracin production by Bacillus licheniformis DW2 through systematic metabolic pathway modification. Several genes encoding rate-limiting enzymes for L-ornithine biosynthesis were episomally overexpressed, including argB, rocF, ppnk1, and ppnk2. The results showed that the overexpression of ppnK1 was the most effective for both L-ornithine and bacitracin biosynthesis. Secondly, the competitive branch pathways for L-ornithine biosynthesis were blocked, and the repressor was also deleted to boost L-ornithine biosynthesis. The results suggested that the deletion of genes proB and proJ to prevent proline biosynthesis and the disruption of the gene encoding the arginine repressor ArgR could enhance the intracellular concentration of L-ornithine by 49% and 2.1 times respectively, and the bacitracin production also increased accordingly by 6.6% and 11.9% respectively. Finally, several most effective efforts were combined to construct the optimal strain DW2ΔproBΔproJΔargR::ppnk1. In the optimal strain, the NADPH availability was improved and the expression levels of several essential genes for L-ornithine biosynthesis were upregulated, resulting in the enhancement of both L-ornithine and bacitracin production by 71.4% and 16.5% respectively. The final bacitracin production titer was 950 U/mL, which reached the level for industrial production.


Assuntos
Anti-Infecciosos Locais/metabolismo , Bacillus licheniformis/metabolismo , Bacitracina/metabolismo , Vias Biossintéticas/genética , Engenharia Metabólica/métodos , Ornitina/metabolismo , Bacillus licheniformis/genética , Deleção de Genes , Expressão Gênica
8.
BMC Vet Res ; 15(1): 377, 2019 Oct 28.
Artigo em Inglês | MEDLINE | ID: mdl-31660968

RESUMO

BACKGROUND: Streptococcus suis is a prominent pathogen causing septicemia and meningitis in swine and humans. Bacitracin is used widely as a growth promoter in animal feed and to control the spread of necrotic enteritis in most developing countries. This study aimed to characterize a novel membrane transporter module Sst comprising SstE, SstF, and SstG for bacitracin resistance. RESULTS: Comparative genomics and protein homology analysis found a potential efflux pump SstFEG encoded upstream of well-known bacitracin-resistance genes bceAB and bceRS. A four-fold decrease in bacitracin susceptibility was observed in sstFEG deletion mutant comparing with S. suis wildtype strain CZ130302. Further studies indicated that the bacitracin tolerance mediated by SstFEG is not only independent of the BceAB transporter, but also regulated by the two-component system BceSR. Given that SstFEG are harbored by almost all virulent strains, but not in the avirulent strains, we managed to explore its potential role in bacterial pathogencity. Indeed, our results showed that SstFEG is involved in S. suis colonization and virulence in animal infection model by its potential competitive survival advantage against host bactericidal effect. CONCLUSION: To our knowledge, this is the first study to functionally characterize the bacitracin efflux pump in S. suis to provide evidence regarding the important roles of the novel ABC transporter system SstFEG with respect to drug resistance and virulence.


Assuntos
Antibacterianos/farmacologia , Bacitracina/farmacologia , Proteínas de Bactérias/metabolismo , Farmacorresistência Bacteriana , Proteínas de Membrana Transportadoras/metabolismo , Streptococcus suis/efeitos dos fármacos , Animais , Antibacterianos/metabolismo , Anti-Infecciosos Locais/metabolismo , Anti-Infecciosos Locais/farmacologia , Bacitracina/metabolismo , Proteínas de Bactérias/genética , Feminino , Deleção de Genes , Regulação Bacteriana da Expressão Gênica , Proteínas de Membrana Transportadoras/genética , Camundongos , Camundongos Endogâmicos BALB C , Testes de Sensibilidade Microbiana , Infecções Estreptocócicas/microbiologia , Streptococcus suis/metabolismo , Streptococcus suis/patogenicidade , Virulência
9.
Mol Microbiol ; 104(1): 16-31, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-27997719

RESUMO

BceRS and PsdRS are paralogous two-component systems in Bacillus subtilis controlling the response to antimicrobial peptides. In the presence of extracellular bacitracin and nisin, respectively, the two response regulators (RRs) bind their target promoters, PbceA or PpsdA , resulting in a strong up-regulation of target gene expression and ultimately antibiotic resistance. Despite high sequence similarity between the RRs BceR and PsdR and their known binding sites, no cross-regulation has been observed between them. We therefore investigated the specificity determinants of PbceA and PpsdA that ensure the insulation of these two paralogous pathways at the RR-promoter interface. In vivo and in vitro analyses demonstrate that the regulatory regions within these two promoters contain three important elements: in addition to the known (main) binding site, we identified a linker region and a secondary binding site that are crucial for functionality. Initial binding to the high-affinity, low-specificity main binding site is a prerequisite for the subsequent highly specific binding of a second RR dimer to the low-affinity secondary binding site. In addition to this hierarchical cooperative binding, discrimination requires a competition of the two RRs for their respective binding site mediated by only slight differences in binding affinities.


Assuntos
Bacillus subtilis/metabolismo , Transportadores de Cassetes de Ligação de ATP/metabolismo , Antibacterianos/farmacologia , Bacillus subtilis/genética , Bacitracina/metabolismo , Proteínas de Bactérias/metabolismo , Sequência de Bases , Sítios de Ligação , Regulação Bacteriana da Expressão Gênica/efeitos dos fármacos , Dados de Sequência Molecular , Nisina/metabolismo , Regiões Promotoras Genéticas , Ligação Proteica/genética , Sequências Reguladoras de Ácido Nucleico , Regulação para Cima
10.
Proc Natl Acad Sci U S A ; 110(35): 14207-12, 2013 Aug 27.
Artigo em Inglês | MEDLINE | ID: mdl-23940351

RESUMO

Bacitracin is a metalloantibiotic agent that is widely used as a medicine and feed additive. It interferes with bacterial cell-wall biosynthesis by binding undecaprenyl-pyrophosphate, a lipid carrier that serves as a critical intermediate in cell wall production. Despite bacitracin's broad use, the molecular details of its target recognition have not been elucidated. Here we report a crystal structure for the ternary complex of bacitracin A, zinc, and a geranyl-pyrophosphate ligand at a resolution of 1.1 Å. The antibiotic forms a compact structure that completely envelopes the ligand's pyrophosphate group, together with flanking zinc and sodium ions. The complex adopts a highly amphipathic conformation that offers clues to antibiotic function in the context of bacterial membranes. Bacitracin's efficient sequestration of its target represents a previously unseen mode for the recognition of lipid pyrophosphates, and suggests new directions for the design of next-generation antimicrobial agents.


Assuntos
Bacitracina/metabolismo , Sequência de Aminoácidos , Bacitracina/química , Membrana Celular/metabolismo , Cristalografia por Raios X , Modelos Moleculares , Dados de Sequência Molecular , Fosfatos de Poli-Isoprenil/metabolismo , Ligação Proteica , Conformação Proteica , Ressonância de Plasmônio de Superfície
11.
J Biol Chem ; 289(40): 27899-910, 2014 Oct 03.
Artigo em Inglês | MEDLINE | ID: mdl-25118291

RESUMO

Resistance against antimicrobial peptides in many Firmicutes bacteria is mediated by detoxification systems that are composed of a two-component regulatory system (TCS) and an ATP-binding cassette (ABC) transporter. The histidine kinases of these systems depend entirely on the transporter for sensing of antimicrobial peptides, suggesting a novel mode of signal transduction where the transporter constitutes the actual sensor. The aim of this study was to investigate the molecular mechanisms of this unusual signaling pathway in more detail, using the bacitracin resistance system BceRS-BceAB of Bacillus subtilis as an example. To analyze the proposed communication between TCS and the ABC transporter, we characterized their interactions by bacterial two-hybrid analyses and could show that the permease BceB and the histidine kinase BceS interact directly. In vitro pulldown assays confirmed this interaction, which was found to be independent of bacitracin. Because it was unknown whether BceAB-type transporters could detect their substrate peptides directly or instead recognized the peptide-target complex in the cell envelope, we next analyzed substrate binding by the transport permease, BceB. Direct and specific binding of bacitracin by BceB was demonstrated by surface plasmon resonance spectroscopy. Finally, in vitro signal transduction assays indicated that complex formation with the transporter influenced the autophosphorylation activity of the histidine kinase. Taken together, our findings clearly show the existence of a sensory complex composed of TCS and ABC transporters and provide the first functional insights into the mechanisms of stimulus perception, signal transduction, and antimicrobial resistance employed by Bce-like detoxification systems.


Assuntos
Transportadores de Cassetes de Ligação de ATP/metabolismo , Antibacterianos/metabolismo , Bacillus subtilis/metabolismo , Bacitracina/metabolismo , Proteínas de Bactérias/metabolismo , Farmacorresistência Bacteriana , Proteínas de Membrana Transportadoras/metabolismo , Proteínas Quinases/metabolismo , Transportadores de Cassetes de Ligação de ATP/genética , Antibacterianos/farmacologia , Bacillus subtilis/efeitos dos fármacos , Bacillus subtilis/enzimologia , Bacillus subtilis/genética , Bacitracina/farmacologia , Proteínas de Bactérias/genética , Histidina Quinase , Proteínas de Membrana Transportadoras/genética , Ligação Proteica , Proteínas Quinases/genética
12.
Cell Biol Int ; 39(4): 373-8, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25319222

RESUMO

Islet amyloid deposition is increasingly seen as a pathogenic feature of type 2 diabetes mellitus (T2DM), with the deposits containing the unique amyloidogenic peptide islet amyloid polypeptide (IAPP, also known as amylin). The fibril precursors of IAPP contribute to its cytotoxicity on pancreatic ß cells and be important in causing ß-cell dysfunction in T2DM. However, the development of effective this study, inhibitors against the toxicity of IAPP has been extremely challenging. We have found that pre-incubation with geniposide dose-dependently prevented human IAPP (hIAPP)-induced cell damage in INS-1E cells, and bacitracin, an inhibitor of IDE activity, prevented significantly the protective effects of geniposide in pancreatic INS-1E cells significantly. Geniposide induced the expression of insulin-degrading enzyme (IDE), a key degrading protein of hIAPP, but had no significant effect on the aggregation of hIAPP. These findings indicate that geniposide prevents hIAPP-induced cytotoxicity in INS-1E cells involving upregulation of IDE expression.


Assuntos
Apoptose/efeitos dos fármacos , Insulisina/metabolismo , Iridoides/farmacologia , Polipeptídeo Amiloide das Ilhotas Pancreáticas/toxicidade , Substâncias Protetoras/farmacologia , Animais , Bacitracina/metabolismo , Linhagem Celular Tumoral , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/patologia , Humanos , Células Secretoras de Insulina/citologia , Células Secretoras de Insulina/efeitos dos fármacos , Células Secretoras de Insulina/metabolismo , Polipeptídeo Amiloide das Ilhotas Pancreáticas/química , Polipeptídeo Amiloide das Ilhotas Pancreáticas/metabolismo , Ratos
13.
Appl Environ Microbiol ; 80(1): 97-103, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24123744

RESUMO

A Streptococcus mutans mutant defective in aciduricity was constructed by random-insertion mutagenesis. Sequence analysis of the mutant revealed a mutation in gidA, which is known to be involved in tRNA modification in Streptococcus pyogenes. Complementation of gidA by S. pyogenes gidA recovered the acid tolerance of S. mutans. Although the gidA-inactivated S. pyogenes mutant exhibited significantly reduced expression of multiple extracellular virulence proteins, the S. mutans mutant did not. On the other hand, the gidA mutant of S. mutans showed reduced ability to withstand exposure to other stress conditions (high osmotic pressure, high temperature, and bacitracin stress) besides an acidic environment. In addition, loss of GidA decreased the capacity for glucose-dependent biofilm formation by over 50%. This study revealed that gidA plays critical roles in the survival of S. mutans under stress conditions, including lower pH.


Assuntos
Proteínas de Bactérias/metabolismo , Viabilidade Microbiana , Streptococcus mutans/fisiologia , Estresse Fisiológico , Ácidos/toxicidade , Antibacterianos/metabolismo , Bacitracina/metabolismo , Proteínas de Bactérias/genética , Biofilmes/crescimento & desenvolvimento , Tolerância a Medicamentos , Técnicas de Inativação de Genes , Teste de Complementação Genética , Temperatura Alta , Concentração de Íons de Hidrogênio , Mutagênese Insercional , Pressão Osmótica , Streptococcus mutans/efeitos dos fármacos , Streptococcus mutans/genética , Streptococcus mutans/efeitos da radiação
14.
J Control Release ; 367: 158-166, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38253205

RESUMO

Mast cells (MCs) are primary effector cells involved in immediate allergic reactions. Mas-related G protein-coupled receptor-X2 (MrgX2), which is highly expressed on MCs, is involved in receptor-mediated drug-induced pseudo-anaphylaxis. Many small-molecule drugs and peptides activate MrgX2, resulting in MC activation and allergic reactions. Although small-molecule drugs can be identified using existing MrgX2 ligand-screening systems, there is still a lack of effective means to screen peptide ligands. In this study, to screen for peptide drugs, the MrgX2 high-affinity endogenous peptide ligand substance P (SP) was used as a recognition group to design a fluorescent peptide probe. Spectroscopic properties and fluorescence imaging of the probe were assessed. The probe was then used to screen for MrgX2 agonists among peptide antibiotics. In addition, the effects of peptide antibiotics on MrgX2 activation were investigated in vivo and in vitro. The environment-sensitive property of the probe was revealed by the dramatic increase in fluorescence intensity after binding to the hydrophobic ligand-binding domain of MrgX2. Based on these characteristics, it can be used for in situ selective visualization of MrgX2 in live cells. The probe was used to screen ten types of peptide antibiotics, and we found that caspofungin and bacitracin could compete with the probe and are hence potential ligands of MrgX2. Pharmacological experiments confirmed this hypothesis; caspofungin and bacitracin activated MCs via MrgX2 in vitro and induced local anaphylaxis in mice. Our research can be expected to provide new ideas for screening MrgX2 peptide ligands and reveal the mechanisms of adverse reactions caused by peptide drugs, thereby laying the foundation for improving their clinical safety.


Assuntos
Anafilaxia , Hipersensibilidade a Drogas , Camundongos , Animais , Receptores de Neuropeptídeos/agonistas , Receptores de Neuropeptídeos/metabolismo , Ligantes , Bacitracina/metabolismo , Bacitracina/farmacologia , Proteínas do Tecido Nervoso/agonistas , Proteínas do Tecido Nervoso/metabolismo , Caspofungina/metabolismo , Caspofungina/farmacologia , Peptídeos/farmacologia , Antibacterianos/farmacologia , Mastócitos/metabolismo , Degranulação Celular/fisiologia
15.
J Bacteriol ; 195(14): 3287-97, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23687272

RESUMO

In the low-G+C-content Gram-positive bacteria, resistance to antimicrobial peptides is often mediated by so-called resistance modules. These consist of a two-component system and an ATP-binding cassette transporter and are characterized by an unusual mode of signal transduction where the transporter acts as a sensor of antimicrobial peptides, because the histidine kinase alone cannot detect the substrates directly. Thus, the transporters fulfill a dual function as sensors and detoxification systems to confer resistance, but the mechanistic details of these processes are unknown. The paradigm and best-understood example for this is the BceRS-BceAB module of Bacillus subtilis, which mediates resistance to bacitracin, mersacidin, and actagardine. Using a random mutagenesis approach, we here show that mutations that affect specific functions of the transporter BceAB are primarily found in the C-terminal region of the permease, BceB, particularly in the eighth transmembrane helix. Further, we show that while signaling and resistance are functionally interconnected, several mutations could be identified that strongly affected one activity of the transporter but had only minor effects on the other. Thus, a partial genetic separation of the two properties could be achieved by single amino acid replacements, providing first insights into the signaling mechanism of these unusual modules.


Assuntos
Antibacterianos/metabolismo , Peptídeos Catiônicos Antimicrobianos/metabolismo , Bacillus subtilis/metabolismo , Farmacorresistência Bacteriana , Proteínas de Membrana Transportadoras/metabolismo , Transdução de Sinais , Bacillus subtilis/genética , Bacitracina/metabolismo , Bacteriocinas/metabolismo , Transporte Biológico Ativo , Análise Mutacional de DNA , Regulação Bacteriana da Expressão Gênica , Proteínas de Membrana Transportadoras/genética , Mutagênese , Peptídeos/metabolismo , Transporte Proteico
16.
J Virol ; 86(8): 4169-81, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22345461

RESUMO

Cell invasion by human papillomavirus type 16 (HPV16) is a complex process relying on multiple host cell factors. Here we describe an investigation into the role of cellular protein disulfide isomerases (PDIs) by studying the effects of the commonly used PDI inhibitor bacitracin on HPV16 infection. Bacitracin caused an unusual time-dependent opposing effect on viral infection. Enhanced cellular binding and entry were observed at early times of infection, while inhibition was observed at later times postentry. Bacitracin was rapidly taken up by host cells and colocalized with HPV16 at late times of infection. Bacitracin had no deleterious effect on HPV16 entry, capsid disassembly, exposure of L1/L2 epitopes, or lysosomal trafficking but caused a stark inhibition of L2/viral DNA (vDNA) endosomal penetration and accumulation at nuclear PML bodies. γ-Secretase has recently been implicated in the endosomal penetration of L2/vDNA, but bacitracin had no effect on γ-secretase activity, indicating that blockage of this step occurs through a γ-secretase-independent mechanism. Transient treatment with the reductant ß-mercaptoethanol (ß-ME) was able to partially rescue the virus from bacitracin, suggesting the involvement of a cellular reductase activity in HPV16 infection. Small interfering RNA (siRNA) knockdown of cellular PDI and the related PDI family members ERp57 and ERp72 reveals a potential role for PDI and ERp72 in HPV infection.


Assuntos
Antivirais/farmacologia , Bacitracina/farmacologia , Endossomos/efeitos dos fármacos , Papillomavirus Humano 16/efeitos dos fármacos , Secretases da Proteína Precursora do Amiloide/metabolismo , Antivirais/metabolismo , Bacitracina/metabolismo , Transporte Biológico/efeitos dos fármacos , Proteínas do Capsídeo/química , Proteínas do Capsídeo/imunologia , Linhagem Celular , Nucléolo Celular/metabolismo , Endocitose , Endossomos/virologia , Epitopos/imunologia , Genoma Viral , Papillomavirus Humano 16/imunologia , Humanos , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/metabolismo , Proteínas Nucleares/metabolismo , Proteínas Oncogênicas Virais/química , Proteínas Oncogênicas Virais/imunologia , Isomerases de Dissulfetos de Proteínas/antagonistas & inibidores , Isomerases de Dissulfetos de Proteínas/genética , Substâncias Redutoras/farmacologia , Internalização do Vírus/efeitos dos fármacos
17.
Poult Sci ; 92(9): 2299-310, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23960112

RESUMO

The turnover of intestinal epithelial cells is a dynamic process that includes adequate cell proliferation and maturation in the presence of microbiota and migration and seeding of immune cells in early gut development in chickens. We studied the effect of yeast-derived macromolecules (YDM) on performance, gut health, and immune system gene expression in the intestine of broiler chickens. One thousand eighty 1-d-old birds, with 60 birds per pen and 6 pens per treatment, were randomly assigned to 3 treatment diets; a diet containing monensin (control), control diet supplemented with bacitracin methylene disalycylate (BMD), and BMD diet supplemented with YDM. Feed intake, BW, mortality, ileum histomorphology, and gene expression of Toll-like receptors (TLR2b, TLR4, and TLR21), cytokines [interferon (IFN)-γ, IFN-ß, IL-12p35, IL-1ß, IL-6, IL-10, IL-8, IL-2, IL-4, and transforming growth factor (TGF)-ß4], and cluster of differentiation (CD)40 in the ileum, cecal tonsil, bursa of Fabricius, and spleen were assessed. No significant overall difference in performance in terms of feed intake, BW gain, and G:F was observed among treatments (P > 0.05). The YDM diet resulted in significantly higher villi height and villi height:crypt depth ratio compared with BMD and control diets (P < 0.05). A significantly lower mortality was observed in the YDM treatment compared with both control and BMD treatments. Compared with the control, gene expression analysis in YDM treatment showed no major change in response in the ileum, whereas higher CD40, IFN-ß, IL-ß, IL-6, TGF-ß4, IL-2, and IL-4 in the cecal tonsil; TLR2b, TLR4, TLR21, and TGF-ß4 in the bursa of Fabricius; and TLR4, IL-12p35, IFN-γ, TGF-ß4, and IL-4 in the spleen was observed (P < 0.05). In conclusion, supplementation of YDM supports pro- and anti-inflammatory cytokine production via T helper type 1 and 2 (Th1 and Th2) cell-associated pathways both locally and systemically with a stronger additive effect in the cecal tonsil in the presence of BMD in the diet of chickens.


Assuntos
Fenômenos Fisiológicos da Nutrição Animal , Galinhas/fisiologia , Suplementos Nutricionais/análise , Regulação da Expressão Gênica , Leveduras/química , Ração Animal/análise , Criação de Animais Domésticos , Animais , Bacitracina/metabolismo , Quimiocinas/genética , Quimiocinas/metabolismo , Galinhas/anatomia & histologia , Galinhas/genética , Galinhas/imunologia , Citocinas/genética , Citocinas/metabolismo , Trato Gastrointestinal/anatomia & histologia , Perfilação da Expressão Gênica/veterinária , Masculino , Monensin/metabolismo , Especificidade de Órgãos , RNA/análise , Reação em Cadeia da Polimerase em Tempo Real/veterinária , Salicilatos/metabolismo , Receptores Toll-Like/genética , Receptores Toll-Like/metabolismo
18.
Mol Microbiol ; 81(3): 602-22, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21696458

RESUMO

Two-component systems (TCSs) are key regulatory pathways allowing bacteria to adapt their genetic expression to environmental changes. Bacitracin, a cyclic dodecylpeptide antibiotic, binds to undecaprenyl pyrophosphate, the lipid carrier for cell wall precursors, effectively inhibiting peptidoglycan biosynthesis. We have identified a novel and previously uncharacterized TCS in the major human pathogen Staphylococcus aureus that we show to be essential for bacitracin and nisin resistance: the BraS/BraR system (Bacitracin resistance associated; SA2417/SA2418). The braRS genes are located immediately upstream from genes encoding an ABC transporter, accordingly designated BraDE. We have shown that the BraSR/BraDE module is a key bacitracin and nisin resistance determinant in S. aureus. In the presence of low antibiotic concentrations, BraSR activate transcription of two operons encoding ABC transporters: braDE and vraDE. We identified a highly conserved imperfect palindromic sequence upstream from the braDE and vraDE promoter sequences, essential for their transcriptional activation by BraSR, suggesting it is the likely BraR binding site. We demonstrated that the two ABC transporters play distinct and original roles in antibiotic resistance: BraDE is involved in bacitracin sensing and signalling through BraSR, whereas VraDE acts specifically as a detoxification module and is sufficient to confer bacitracin and nisin resistance when produced on its own. We show that these processes require functional BraD and VraD nucleotide-binding domain proteins, and that the large extracellular loop of VraE confers its specificity in bacitracin resistance. This is the first example of a TCS associated with two ABC transporters playing separate roles in signal transduction and antibiotic resistance.


Assuntos
Transportadores de Cassetes de Ligação de ATP/metabolismo , Peptídeos Catiônicos Antimicrobianos/metabolismo , Bacitracina/metabolismo , Farmacorresistência Bacteriana , Regulação Bacteriana da Expressão Gênica , Nisina/metabolismo , Staphylococcus aureus/metabolismo , Adaptação Fisiológica , Sequência de Aminoácidos , Bacitracina/farmacologia , Sequência de Bases , Humanos , Testes de Sensibilidade Microbiana , Modelos Biológicos , Dados de Sequência Molecular , Família Multigênica , Nisina/farmacologia , Óperon , Regiões Promotoras Genéticas , Alinhamento de Sequência , Transdução de Sinais , Staphylococcus aureus/efeitos dos fármacos , Staphylococcus aureus/genética
19.
Appl Environ Microbiol ; 78(22): 7903-14, 2012 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-22941078

RESUMO

Bacillus spp. are widely used as feed additives and probiotics. However, there is limited information on their resistance to various antibiotics, and there is a growing concern over the transfer of antibiotic resistance genes. The MIC for 8 antibiotics was determined for 85 Bacillus species strains, Bacillus subtilis subsp. subtilis (n = 29), Bacillus licheniformis (n = 38), and Bacillus sonorensis (n = 18), all of which were isolated from starters for Sudanese bread production. All the strains were sensitive to tetracycline (8.0 mg/liter), vancomycin (4.0 mg/liter), and gentamicin (4.0 mg/liter) but resistant to streptomycin. Sensitivity to clindamycin, chloramphenicol, and kanamycin was species specific. The erythromycin resistance genes ermD and ermK were detected by PCR in all of the erythromycin-resistant (MIC, ≥16.0 mg/liter) B. licheniformis strains and one erythromycin-sensitive (MIC, 4.0 mg/liter) B. licheniformis strain. Several amino acid changes were present in the translated ermD and ermK nucleotide sequences of the erythromycin-sensitive strain, which could indicate ErmD and ErmK protein functionalities different from those of the resistance strains. The ermD and ermK genes were localized on an 11.4-kbp plasmid. All of the B. sonorensis strains harbored the bacitracin synthetase gene, bacA, and the transporter gene bcrA, which correlated with their observed resistance to bacitracin. Bacitracin was produced by all the investigated species strains (28%), as determined by ultra-high-definition quadrupole time-of-flight liquid chromatography-mass spectrometry (UHD-QTOF LC/MS). The present study has revealed species-specific variations in the antimicrobial susceptibilities of Bacillus spp. and provides new information on MIC values, as well as the occurrence of resistance genes in Bacillus spp., including the newly described species B. sonorensis.


Assuntos
Antibacterianos/metabolismo , Antibacterianos/farmacologia , Bacillus/efeitos dos fármacos , Bacillus/isolamento & purificação , Bacitracina/metabolismo , Pão/microbiologia , Redes e Vias Metabólicas/genética , Bacillus/química , Bacillus/classificação , Cromatografia Líquida , Espectrometria de Massas , Testes de Sensibilidade Microbiana , Dados de Sequência Molecular , Óperon , Análise de Sequência de DNA
20.
Parasitol Res ; 110(5): 1911-7, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22160278

RESUMO

Leishmaniasis is a major health problem worldwide and tools available for their control are limited. Effective vaccines are still lacking, drugs are toxic and expensive, and parasites develop resistance to chemotherapy. In this context, new antimicrobials are urgently needed to control the disease in both human and animal. Here, we report the enzymatic and functional characterization of a Leishmania virulence factor, Leishmania major Protein disulfide isomerase (LmPDI) that could constitute a potential drug target. LmPDI possesses domain structure organization similar to other PDI family members (a, a', b, b' and c domains), and it displays the three enzymatic and functional activities specific of PDI family members: isomerase, reductase and chaperone. These results suggest that LmPDI plays a key role in assisting Leishmania protein folding via its capacity to catalyze formation, breakage, and rearrangement of disulfide bonds in nascent polypeptides. Moreover, Bacitracin, a reductase activity inhibitor, and Ribostamycin, a chaperone activity inhibitor, were tested in LmPDI enzymatic assays and versus Leishmania promastigote in vitro cultures and Leishmania amastigote multiplication inside infected THP-1-derived macrophages. Bacitracin inhibited both isomerase and reductase activities, while Ribostamycin had no effect on the chaperone activity. Interestingly, Bacitracin blocked in vitro promastigote growth as well as amastigote multiplication inside macrophages with EC(50) values of 39 µM. These results suggest that LmPDI may constitute an interesting target for the development of new anti-Leishmania drugs.


Assuntos
Leishmania major/enzimologia , Isomerases de Dissulfetos de Proteínas/metabolismo , Fatores de Virulência/metabolismo , Animais , Antiprotozoários/metabolismo , Bacitracina/metabolismo , Linhagem Celular , Dissulfetos/metabolismo , Inibidores Enzimáticos/metabolismo , Humanos , Leishmania major/efeitos dos fármacos , Leishmania major/crescimento & desenvolvimento , Monócitos/parasitologia , Isomerases de Dissulfetos de Proteínas/antagonistas & inibidores , Dobramento de Proteína , Ribostamicina/metabolismo , Fatores de Virulência/antagonistas & inibidores
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa